Trial Profile

A randomised-controlled trial of IXCHIQ outside of Brazil

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Aug 2024 New trial record
22 Jul 2024 According to a Valneva media release, trial partners, including clinical research organisations and trial sponsors, are expected to be selected over the coming months.
22 Jul 2024 According to a Valneva media release, the company plans to trial to determine efficacy of Ixchiq in an outbreak setting in a LMIC - Part- funded by CEPI and the EU's Horizon Europe program as part of a trial in 20,000 participants to determine vaccine efficacy in a randomized-controlled trial outside of Brazil. The trial is expected to start in 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com